Panacela Labs Inc. was founded in 2011 by biotechnology company Cleveland Biolabs, Inc (CBLI), Buffalo, USA, NASDAQ: CBLI) with a focus on oncology and orphan drug development, some drugs of which are on the stage of clinical studies, and Open Joint Stock Company “RUSNANO”, the largest Russian investment company.

Panacela Labs – clinical stage biotech company developing the innovative anticancer drug product in collaboration with the Roswell Park Cancer Institute (Buffalo, USA) and Cleveland Clinic Foundation (Cleveland, USA).

Since 2011 company Panacela Labs has gone all the way to development of a new drug: from the concept, through selection and optimization and preclinical trials – to clinical studies. Currently clinical trials are carried out in Russia through the affiliated company structure – Limited Liability Company “Panacela Labs” which has been a member of Skolkovo Innovation Center since 2012.
Pilot clinical results demonstrate excellent safety and tolerability over the range of studied doses as well as induction of several biomarkers suggesting possilbe efficacy of the drug.